Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 19, 2026

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

View original at globenewswire.com
NovaBridge Appoints Biotech Leader, Emmett T…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet AMD and DME

    80% confidence

  • VIS-101 is a second-in-class, potentially best-in-class bifunctional biologic targeting VEGF-A and ANG2

    80% confidence

  • NovaBridge's unique global biotech platform has potential to bridge the gap between unmet patient needs and transformative care

    80% confidence

  • Dr. Cunningham's distinguished career as a physician and proven entrepreneur, combined with his expertise in accelerating early-stage programs across several therapeutic areas, perfectly complements NovaBridge's unique hub-and-spoke business model

    80% confidence

  • Givastomig is a potential best-in-class, Claudin 18.2 x 4-1BB bispecific antibody

    80% confidence

Cited in these Via News reports